The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Congress will take place April 21-24, 2025, in Washington, D.C. COPENHAGEN, Denmark, April 10, 2025 - Evaxion Biotech A/S (NASDAQ: EVAX) ("Evaxion”), a clinical-stage TechBio company specializing in ...

Check Out Our Latest Stock Report on EVAX Evaxion Biotech A/S Stock Performance Shares of EVAX opened at $1.51 on Friday. Evaxion Biotech A/S has a 1 year low of $1.50 and a 1 year high of $22.05 ...

Evaxion Biotech A/S (NASDAQ:EVAX) Q4 2024 Earnings Call Transcript April 1, 2025 Evaxion Biotech A/S misses on earnings expectations. Reported EPS is $-0.07 EPS, expectations were $-0.03.

Shares of LMFA opened at $1.22 on Wednesday. The company has a debt-to-equity ratio of 0.17, a quick ratio of 3.65 and a current ratio of 3.65. LM Funding America has a fifty-two week low of $1.19 ...

Evaxion Biotech AS (NASDAQ:EVAX) entered into a transformational partnership with MSD in September 2024, which is tracking well towards potential option exercise in the second half of 2025.

Evaxion Biotech AS (NASDAQ:EVAX) entered into a transformational partnership with MSD in September 2024, which is tracking well towards potential option exercise in the second half of 2025. The ...

The latest price target for Evaxion Biotech (NASDAQ:EVAX) was reported by HC Wainwright & Co. on April 2, 2025. The analyst firm set a price target for $14.00 expecting EVAX to rise to within 12 ...

Good day, and thank you for standing by. Welcome to the Evaxion Biotech Business Update Full Year 2024 Conference Call and Webcast. At this time, all participants will be in listen-only mode ...

Evaxion (NASDAQ:EVAX) is a clinical stage company that is making AI useful in the current environment by using the technology to develop new cancer-fighting vaccines. The company notes that it has ...